{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T21:26:43Z","timestamp":1768685203186,"version":"3.49.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2003,11,1]],"date-time":"2003-11-01T00:00:00Z","timestamp":1067644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2003,11,1]],"date-time":"2003-11-01T00:00:00Z","timestamp":1067644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Doc Ophthalmol"],"published-print":{"date-parts":[[2003,11]]},"DOI":"10.1023\/b:doop.0000005337.39947.83","type":"journal-article","created":{"date-parts":[[2003,11,26]],"date-time":"2003-11-26T09:04:47Z","timestamp":1069837487000},"page":"281-287","source":"Crossref","is-referenced-by-count":31,"title":["Examining visual field defects in the paediatric population exposed to vigabatrin"],"prefix":"10.1007","volume":"107","author":[{"given":"E.L.","family":"Spencer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.F.A.","family":"Harding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"issue":"Suppl.61","key":"5118724_CR1","first-page":"3","volume":"42","author":"E Perucca","year":"1988","unstructured":"Perucca E. Efficacy and tolerability with long-term administration of vigabatrin. Br J Clin Pract 1988; 42 (Suppl. 61):3.","journal-title":"Br J Clin Pract"},{"key":"5118724_CR2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S1059-1311(05)80077-9","volume":"4","author":"RE Appleton","year":"1995","unstructured":"Appleton RE. Vigabatrin in the management of generalized seizures in children. Seizure1995; 4: 45\u20138.","journal-title":"Seizure"},{"issue":"2","key":"5118724_CR3","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/S0022-3565(25)24999-0","volume":"238","author":"JF Cubells","year":"1986","unstructured":"Cubells JF, Blanchard JS, Smith DM, Makman MH. In vivo action of enzyme-activated irreversible inhibitors of glutamic acid decarboxylase and ?-aminobutyric acid transaminase in retina vs. brain. J Pharmacol Exp Ther 1986; 238(2): 508\u201314.","journal-title":"J Pharmacol Exp Ther"},{"key":"5118724_CR4","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1136\/bmj.314.7075.180","volume":"314","author":"T Eke","year":"1997","unstructured":"Eke T, Talbot J, Lawden MC. Severe persistent visual field constriction associated with vigabatrin. Br Med J 1997; 314:180\u20131.","journal-title":"Br Med J"},{"key":"5118724_CR5","first-page":"1694","volume":"314","author":"GFA Harding","year":"1997","unstructured":"Harding GFA. Severe persistent visual field constriction associated with vigabatrin. Four possible mechanisms exist. Br Med J 1997; 314: 1694.","journal-title":"Br Med J"},{"key":"5118724_CR6","first-page":"814","volume":"50","author":"GL Krauss","year":"1998","unstructured":"Krauss GL, Johnson MA, Miller NR. Vigabatrin-associated retinal cone system dysfunction. Electroretinogram Ophthalmol Find Neurol 1998; 50: 814\u20139.","journal-title":"Electroretinogram Ophthalmol Find Neurol"},{"key":"5118724_CR7","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1212\/WNL.52.6.1201","volume":"52","author":"CF Arndt","year":"1999","unstructured":"Arndt CF, Derambure P, Defoort-Dhellemmes S, Hache JC. Outer retinal dysfunction in patients treated with vigabatrin. Neurology 1999; 52: 1201\u20135.","journal-title":"Neurology"},{"key":"5118724_CR8","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1016\/S0161-6420(99)90345-7","volume":"106","author":"H Daneshvar","year":"1999","unstructured":"Daneshvar H, Racette L, Coupland SG, Kertes PJ, Guberman A, Zakon D. Symptomatic and asymptomatic visual loss in patients taking vigabatrin. Ophthalmology 1999; 106: 1792\u20138.","journal-title":"Ophthalmology"},{"key":"5118724_CR9","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1212\/WNL.53.5.922","volume":"53","author":"R Kalvianien","year":"1999","unstructured":"Kalvianien R, Nousiainen I, Mantyjarvi M, et al. Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field constriction. Neurology 1999; 53: 922\u20136.","journal-title":"Neurology"},{"key":"5118724_CR10","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1136\/jnnp.67.6.716","volume":"67","author":"MC Lawden","year":"1999","unstructured":"Lawden MC, Eke T, Degg C, Harding GFA, Wild JM. Visual field defects associated with vigabatrin therapy. J Neurol, Neurosurg Psychiatry 1999; 67: 716\u201322.","journal-title":"J Neurol, Neurosurg Psychiatry"},{"key":"5118724_CR11","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1111\/j.1528-1157.1999.tb01599.x","volume":"40","author":"JM Wild","year":"1999","unstructured":"Wild JM, Martinez C, Reinshagen G, Harding GFA. Characteristics of a unique visual field defect attributed to vigabatrin. Epilepsia 1999; 40: 1784\u201394.","journal-title":"Epilepsia"},{"key":"5118724_CR12","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1212\/WNL.53.9.2082","volume":"53","author":"NR Miller","year":"1999","unstructured":"Miller NR, Johnson MA, Paul SR, et al. Visual dysfunction in patients receiving vigabatrin. Clinical and electrophysiological findings. Neurology 1999; 53: 2082\u20137.","journal-title":"Neurology"},{"key":"5118724_CR13","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1046\/j.1528-1157.2001.49299.x","volume":"42","author":"SR Paul","year":"2001","unstructured":"Paul SR, Krauss GL, Miller NR, Medura MT, Miller TA, Johnson MA. Visual function is stable in patients who continue long-term vigabatrin therapy: Implicationsfor clinical decision making. Epilepsia 2001; 42: 525\u201330.","journal-title":"Epilepsia"},{"key":"5118724_CR14","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1046\/j.1528-1157.2001.28600.x","volume":"42","author":"K Malmgren","year":"2001","unstructured":"Malmgren K, Ben-Menachem E, Fris\u00e9n L. Vigabatrin visual toxicity: Evolution and dose dependence. Epilepsia 2001; 42: 609\u201315.","journal-title":"Epilepsia"},{"key":"5118724_CR15","first-page":"262","volume":"42","author":"P Hardus","year":"2001","unstructured":"Hardus P, Verduin WM, Engelsman M, et al. Visual field loss associated with vigabatrin: Quantification and relation to dosage. Epilepsia 2001; 42: 262\u20137.","journal-title":"Epilepsia"},{"key":"5118724_CR16","first-page":"16","volume":"61","author":"EJ Hammond","year":"1989","unstructured":"Hammond EJ, Rangel RJ, Wilder BJ. Evoked potential monitoring of vigabatrin patients. Br J Clin Pract 1989; 61: 16\u201323.","journal-title":"Br J Clin Pract"},{"key":"5118724_CR17","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1365-2125.1989.tb03463.x","volume":"27","author":"V Cosi","year":"1989","unstructured":"Cosi V, Callieco R, Galimberti CA, et al. Effects of vigabatrin on evoked potentialsin epileptic patients. Br J Clin Pharmacol 1989; 27: 61\u20138S.","journal-title":"Br J Clin Pharmacol"},{"key":"5118724_CR18","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1111\/j.1528-1157.1989.tb05829.x","volume":"30","author":"C Liegeois-Chauvel","year":"1989","unstructured":"Liegeois-Chauvel C, Marquis P, Gisselbrecht D, Pantieri R, Beaumont D, Chauvel P. Effectsof long-term vigabatrin on somatosensory-evoked potentials in epileptic patients. Epilepsia 1989; 30: S23\u20135.","journal-title":"Epilepsia"},{"key":"5118724_CR19","doi-asserted-by":"crossref","first-page":"S108","DOI":"10.1111\/j.1528-1157.1995.tb01674.x","volume":"36","author":"GFA Harding","year":"1995","unstructured":"Harding GFA, Jones LA, Tipper VJ, Betts TA, Mumford JP. Electroretinogram, pattern electroretinogram and visual evoked potential assessment in patients receiving vigabatrin. Epilepsia 1995; 36: S108.","journal-title":"Epilepsia"},{"key":"5118724_CR20","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1528-1157.1995.tb01661.x","volume":"36","author":"F Maugui\u00e9re","year":"1995","unstructured":"Maugui\u00e9re F, Chauvel P, Dewailly J, Dousse N. No Effect of long-term vigabatrin treatment on CNS conduction in epileptic patients: results of a multicenter study of somatosensory and visual evoked potentials. Epilepsia 1995; 36: 29.","journal-title":"Epilepsia"},{"key":"5118724_CR21","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1023\/A:1002045223358","volume":"97","author":"GFA Harding","year":"1999","unstructured":"Harding GFA, Robertson KA, Edson AS, Barnes P, Wild JM. Visual electrophysiological effect of a GABA transaminase blocker. Doc Ophthalmol. 1999; 97: 179\u201388.","journal-title":"Doc Ophthalmol"},{"issue":"3","key":"5118724_CR22","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1212\/WNL.55.3.347","volume":"55","author":"GFA Harding","year":"2000","unstructured":"Harding GFA, Wild JM, Robertson KA, Rietbrock S, Martinez C. Separating the retinal electrophysiologic effects of vigabatrin - treatment versus field loss. Neurology 2000; 55(3): 347\u201352.","journal-title":"Neurology"},{"issue":"11","key":"5118724_CR23","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1111\/j.1528-1157.2000.tb00117.x","volume":"41","author":"GFA Harding","year":"2000","unstructured":"Harding GFA, Wild JM, Robertson K, et al. EOGs, ERGs, VEPs and multifocal ERGs in epileptic patients showing visual field constriction. Epilepsia 2000; 41(11): 1420\u201331.","journal-title":"Epilepsia"},{"key":"5118724_CR24","doi-asserted-by":"crossref","first-page":"2S52","DOI":"10.1177\/0883073891006002101","volume":"6","author":"C Chiron","year":"1991","unstructured":"Chiron C, Dulac O, Beaumont D, Palacios L, Pajot N, Mumford J. Therapeutic trial of vigabatrin in refactory infantile spasms. J Child Neurol 1991; 6: 2S52\u20139.","journal-title":"J Child Neurol"},{"key":"5118724_CR25","first-page":"171P","volume":"518P","author":"GFA Harding","year":"1999","unstructured":"Harding GFA, Robertson K, Holliday I, Jones L. Field-specific visual evoked potentials for assessment of peripheral field defect in a paediatric population. J Physiol 1999; 518P: 171P.","journal-title":"J Physiol"},{"key":"5118724_CR26","doi-asserted-by":"crossref","unstructured":"Harding GFA, Robertson KA, Holliday I. Field specific visual evoked potentials for assessment of peripheral field defect in a paediatric population. In: Ambler Z, Nev\u00fe\u00edmalov\u00e1 S, Kada\u00f3ka Z, Rossini PM, eds. Clinical neurophysiology at the beginning of the 21st century. Supplements to Clin Neurophysiol 2000; 53: 323\u201330.","DOI":"10.1016\/S1567-424X(09)70175-8"},{"key":"5118724_CR27","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1212\/WNL.58.8.1261","volume":"58","author":"GFA Harding","year":"2002","unstructured":"Harding GFA, Spencer EL, Wild JM, Conway M, Bohn, RL. Field-specific visual evoked potentials: Identifying field defectsin Vigabatrin-treated children. Neurology 2002; 58:1261\u20135.","journal-title":"Neurology"},{"key":"5118724_CR28","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1023\/A:1002016531591","volume":"97","author":"MF Marmor","year":"1998","unstructured":"Marmor MF, Zrenner E. Standard for clinical electroretinography. Doc Ophthalmol 1998; 97: 143\u201356.","journal-title":"Doc Ophthalmol"}],"container-title":["Documenta Ophthalmologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/B:DOOP.0000005337.39947.83.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1023\/B:DOOP.0000005337.39947.83\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/B:DOOP.0000005337.39947.83.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T03:52:09Z","timestamp":1753761129000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1023\/B:DOOP.0000005337.39947.83"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,11]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2003,11]]}},"alternative-id":["5118724"],"URL":"https:\/\/doi.org\/10.1023\/b:doop.0000005337.39947.83","relation":{},"ISSN":["0012-4486","1573-2622"],"issn-type":[{"value":"0012-4486","type":"print"},{"value":"1573-2622","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,11]]}}}